BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 37865045)

  • 1. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
    Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
    EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
    Hayase E; Jenq RR
    Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.
    Renga G; Nunzi E; Pariano M; Puccetti M; Bellet MM; Pieraccini G; D'Onofrio F; Santarelli I; Stincardini C; Aversa F; Riuzzi F; Antognelli C; Gargaro M; Bereshchenko O; Ricci M; Giovagnoli S; Romani L; Costantini C
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35236743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance.
    Park JS; Gazzaniga FS; Wu M; Luthens AK; Gillis J; Zheng W; LaFleur MW; Johnson SB; Morad G; Park EM; Zhou Y; Watowich SS; Wargo JA; Freeman GJ; Kasper DL; Sharpe AH
    Nature; 2023 May; 617(7960):377-385. PubMed ID: 37138075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
    Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
    BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity.
    Huang TX; Tan XY; Huang HS; Li YT; Liu BL; Liu KS; Chen X; Chen Z; Guan XY; Zou C; Fu L
    Gut; 2022 Feb; 71(2):333-344. PubMed ID: 33692094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer.
    Zhang SL; Mao YQ; Zhang ZY; Li ZM; Kong CY; Chen HL; Cai PR; Han B; Ye T; Wang LS
    Theranostics; 2021; 11(9):4155-4170. PubMed ID: 33754054
    [No Abstract]   [Full Text] [Related]  

  • 8. The Microbiome in Advanced Melanoma: Where Are We Now?
    Fortman DD; Hurd D; Davar D
    Curr Oncol Rep; 2023 Sep; 25(9):997-1016. PubMed ID: 37269504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TIGIT
    Tsakmaklis A; Farowski F; Zenner R; Lesker TR; Strowig T; Schlößer H; Lehmann J; von Bergwelt-Baildon M; Mauch C; Schlaak M; Knuever J; Schweinsberg V; Heinzerling LM; Vehreschild MJGT
    BMC Cancer; 2023 Nov; 23(1):1160. PubMed ID: 38017389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
    Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
    Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Si W; Liang H; Bugno J; Xu Q; Ding X; Yang K; Fu Y; Weichselbaum RR; Zhao X; Wang L
    Gut; 2022 Mar; 71(3):521-533. PubMed ID: 33685966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut Microbiota and Therapy in Metastatic Melanoma: Focus on MAPK Pathway Inhibition.
    Guardamagna M; Berciano-Guerrero MA; Villaescusa-González B; Perez-Ruiz E; Oliver J; Lavado-Valenzuela R; Rueda-Dominguez A; Barragán I; Queipo-Ortuño MI
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy.
    Wu J; Wang S; Zheng B; Qiu X; Wang H; Chen L
    Front Immunol; 2021; 12():669150. PubMed ID: 34267748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The intestinal microbial metabolite desaminotyrosine is an anti-inflammatory molecule that modulates local and systemic immune homeostasis.
    Wei Y; Gao J; Kou Y; Liu M; Meng L; Zheng X; Xu S; Liang M; Sun H; Liu Z; Wang Y
    FASEB J; 2020 Dec; 34(12):16117-16128. PubMed ID: 33047367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.
    Li Y; Wang S; Lin M; Hou C; Li C; Li G
    Front Med; 2022 Jun; 16(3):307-321. PubMed ID: 35648368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy.
    Davar D; Zarour HM
    Clin Cancer Res; 2022 Oct; 28(20):4370-4384. PubMed ID: 35748749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Antibiotic Exposure With Survival and Toxicity in Patients With Melanoma Receiving Immunotherapy.
    Mohiuddin JJ; Chu B; Facciabene A; Poirier K; Wang X; Doucette A; Zheng C; Xu W; Anstadt EJ; Amaravadi RK; Karakousis GC; Mitchell TC; Huang AC; Shabason JE; Lin A; Swisher-McClure S; Maity A; Schuchter LM; Lukens JN
    J Natl Cancer Inst; 2021 Feb; 113(2):162-170. PubMed ID: 32294209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
    Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
    Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
    Dora D; Bokhari SMZ; Aloss K; Takacs P; Desnoix JZ; Szklenárik G; Hurley PD; Lohinai Z
    Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.